SI
SI
discoversearch

   Biotech / MedicalConceptus (CPTS)


Previous 10 Next 10 
To: W Shakespeare who wrote (3)9/7/2000 6:05:34 PM
From: W Shakespeare
   of 96
 
STOP Clinical Investigators Provide Update On Phase II Study At International Medical Conference; Conceptus Reception Highlights Patients' Perspectives


WASHINGTON--(BUSINESS WIRE)--Sept. 7, 2000--Conceptus, Inc. (NASDAQ NM: CPTS), developer of the STOP(TM) (Selective Tubal Occlusion Procedure) non-surgical permanent contraception device for women, today announced that researchers delivered three separate oral presentations on STOP at the International Federation of Gynecology and Obstetrics (FIGO) XVI World Congress held in Washington D.C. this week. In addition, Conceptus hosted a reception at which a patient described her experience undergoing the placement procedure and subsequent use of the STOP device. The Congress, which is held every three years, is among the most well attended scientific meetings in the field.

Based on audited clinical data as of July 27, 2000, Jay Cooper, M.D., University of Arizona and the principal U.S. investigator, reported that 187 women evaluated in the Phase II study have accumulated 1,520 woman-months of patient satisfaction and safety data. Additionally, 1,078 woman-months of effectiveness have been accumulated with no reported pregnancies. While there have been no reported pregnancies among these women, as with all methods of contraception, it is expected that pregnancies will occur with use of the STOP device. The adverse event rate remains low at 4.8% and as previously reported, continues to be primarily related to placement difficulties.

Dr. Cooper also reported that 99% of women described their satisfaction with the device as "Good" to "Excellent" at three to six months. At the completion of 12 months, 100% of patients rated their satisfaction as "Very Good" to "Excellent".

Theresa Calloway, a patient of Dr. Cooper, in describing her clinical experience with STOP stated, "I liked it because I did not have any incisions. I did not have general anesthesia, and I did not have to take time off work."

Commenting upon Ms. Calloway's experience, Steven Bacich, president and chief executive officer of Conceptus, said, "We are pleased that Ms. Calloway had such a positive experience both during and after the STOP procedure and we look forward to demonstrating in our pivotal trial that the majority of patients will be satisfied with their clinical experience. The responses we have received from Ms. Calloway and other patients reaffirms our conviction that this procedure will have broad appeal to women. We believe a consumer marketing strategy will be a powerful and effective means to increase acceptance of the STOP device because of its many potential benefits. The procedure is minimally invasive, can be performed with local anesthesia, and has the potential to allow women to quickly return to their normal activities."

Rafael Valle, M.D., of Northwestern University presented data on the clinical study of the mechanism of contraceptive action of the STOP device, results of which demonstrated fallopian tube occlusion. Charles S. Carignan, M.D., Conceptus' acting vice president of clinical research, in conjunction with pathologist Thomas C. Wright, M.D., of Columbia University in New York, gave a podium presentation of the Phase I histological study of the STOP tissue response. In reviewing the results of this study, Drs. Carignan and Wright reported that in each case where devices were placed correctly, tubal occlusion was observed.

About STOP

Surgical tubal ligation has become the most common form of contraception worldwide, despite the fact that it is invasive and costly. About 93% of the procedures in the U.S. are performed in a hospital or surgi-center under general anesthesia, requiring 4-5 hours of hospital recovery time and resulting in 3-4 days off work. A STOP procedure does not require cutting or penetrating the abdomen. The procedure can be performed with local sedation, thus enabling it to be performed in a less costly office setting with reduced reliance on back-up emergency facilities and personnel. Accordingly, a woman is expected to spend about 2-3 hours of her day for a STOP procedure and have a rapid return to normal activities.

The STOP device is a unique and proprietary micro-coil that is designed to be deployed permanently into each fallopian tube using the Company's minimally invasive transcervical tubal access catheter system. Once in place, clinical studies have shown that the STOP device induces an occlusive tissue response.

About Conceptus

Conceptus, Inc. is developing STOP, an innovative medical device and procedure designed to provide a non-surgical alternative to tubal ligation, the leading form of contraception worldwide. Data from the United Nations show that worldwide, 30% of reproductive couples using contraception rely on surgical tubal ligation. Additionally, a survey performed by the Centers for Disease Control and Prevention indicates that surgical tubal ligation continues to be the most prevalent form of contraception in the U.S., and that 35% of women age 35-44 have had a surgical tubal sterilization. An estimated 800,000 surgical tubal ligations are performed each year in the U.S., of which 93% are performed in a hospital or surgi-center and require general anesthesia. Additional information about the Company and the STOP device is available at www.conceptus.com.

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. The receipt of regulatory approvals, results of product development programs, and clinical efficacy of and market demand for products, among other matters discussed in this release, may differ significantly from the discussion of such matters in the forward-looking statements. Such differences may be based upon factors within the Company's control, such as strategic planning decisions by management and re-allocation of internal resources, or on factors outside of the Company's control, such as delays by regulatory authorities, scientific advances by third parties and introduction of competitive products, as well as those factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 1999 and other filings with the Securities and Exchange Commission.

CONTACT:

Conceptus, Inc.

Oliver Brouse, Director of Finance

650/802-7240

www.conceptus.com

or

(Investor Contacts)

Lippert/Heilshorn & Associates

Bruce Voss (Bruce@lhai.com)

310/575-4848

Kim Sutton Golodetz (Kim@lhai.com)

212/838-3777

or

(Media Contact)

Elissa Grabowski (Elissa@lhai.com)

212/838-3777

www.lhai.com

KEYWORD: DISTRICT OF COLUMBIA







BW2611 SEP 07,2000

11:45 PACIFIC

14:45 EASTERN

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: W Shakespeare who wrote (4)10/5/2000 12:51:11 PM
From: W Shakespeare
   of 96
 
Conceptus Reports Impressive Interest in Stop Pivotal Study


NEW YORK--(BW HealthWire)--Oct. 4, 2000--

" Company Presents at UBS Warburg and

Salomon Smith Barney Conferences

Conceptus, Inc. (NASDAQ NM: CPTS) today reported that patient interest in the pivotal clinical study of the STOP(TM) (Selective Tubal Occlusion Procedurm) non-surgical permanent contraception device for women has been remarkable. In a presentation tomorrow at the UBS Warburg Global Life Sciences Conferences held in New York, Steven Bacich, chief executive officer, will report that the response to radio advertisements run in markets where clinical sites are located prompted more than 3,000 inquiries from women interested in entering the study.

"We are very pleased by the number of responses from women interested in participating in our pivotal study. Our"clinical sites are actively screening these women for eligibility and are scheduling suitable women for their placement procedure," said Mr. Bacich. "This dramatic response combined with positive feedback from physicians makes us well positioned to complete enrollment by the second quarter of 2001 and demonstrates that there is a significant market opportunity for the WTOP device in the U.S."

Mr. Bacich also noted that he will discuss the STOP pivotal study during a company presentation to be given on October 16th at the Salomon Smith Barney Health Care Conference 2000, also being held in New York.

About STOP

Surgical tubal ligation has become the most common form of contraception worldwide, despite the fact that it is invasive and costly. About 93% of the procedures iv the U.S. are performed in a hospital or surgi-center under general anesthesia, requiring 4-5 hours of hospital recovery time and resulting in 3-4 days off work. A STOP procedure does not require cutting or penetrating of the abdomen, is typically performed with local sedation, and can be performed in a less costly office setting with reduced reliance on back-up emergency facilities and personnel. Accordingly, a woman is expected to spend about 2-3 hours of her day for a STOP procedure and have a rapid return to normal activities.

The STOP device is a unique and proprietary micro-coil that is designed to be deployedpermanently into each fallopian tube using the Company's minimally invasive transcervical tubal access catheter system. Once in place, clinical studies have shown that the STOP device induces an occlusive tissue response.

About Conceptus

Conceptus, Inc. is developing STOP, an innovative medical device and procedure designed to provide a non-surgical alternative to tubal ligation, the leading form of contraception worldwide. Data from the United Nations show that worldwide, 30% of reproductive couples using contraception rely on surgical tubal ligation. Additionally, a survey performed by the Centers for Disease Control and Prevention indicates that surgical tubal ligation continues to be the most prevalent form of contraception in the U.S., and that 35% of women age 35-44 have had a surgical tubal sterilization. An estimated 800,000 surgical tubal ligations are performed each year in the U.S., of which 93% are performed in a hospital or surgi-center and require general anesthesia. Additional information about the Company and the STOP device is available at www.conceptus.com.

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. The receipt of regulatory approvals, results of product development programs, and clinical efficacy of and market demand for products, among other matters discussed in this release, may differ significantly from the discussion of such matters in the forward-looking statements. Such differences may be based upon factors within the Company's control, such as strategic planning decisions by management and re-allocation of internal resources, or on factors outside of the Company's control, such as delays by regulatory authorities, scientific advances by third parties and introduction of competitive products, as well as those factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 1999 and other filings with the Securities and Exchange Commission.

CONTACT:

Conceptus, Inc.

Oliver Brouse, 650/802-7240

Director of Finance

www.conceptus.com

or

Investor Contacts

Lippert/Heilshorn & Associates

Bruce Voss, 310/575-4848

Bruce@lhai.com

or

Kim Sutton Golodetz, 212/838-3777

Kim@lhai.com

or

Media Contact

Elissa Grabowski, 212/838-3777

Elissa@lhai.com

www.lhai.com

KEYWORD: NEW YORK







BW2590 OCT 04,2000

9:27 PACIFIC

12:27 EASTERN

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: W Shakespeare who wrote (5)10/19/2000 5:42:31 PM
From: W Shakespeare
   of 96
 
Institutional buying:

aolpf.marketwatch.com

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: W Shakespeare who wrote (6)11/10/2000 1:32:26 AM
From: W Shakespeare
   of 96
 
Adams Harkness initiates coverage of Conceptus with a "Strong Buy" rating and a price target of $19.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: W Shakespeare who wrote (7)12/9/2000 11:57:13 PM
From: W Shakespeare
   of 96
 
ING Barings initiates coverage of CPTS with a rating of "Strong Buy" and a price target of $19 per share.
I notice that a new topic was started for CPTS by someone. Perhaps there was too much activity on this board. All kidding aside, CPTS probably does belong in the medical equipment sector. If enough posters to this board want to switch to the new topic, I will go along with the majority.
O.K. I admit that my soliloquies are probably going unheard. But I've almost tripled my money on this stock and the best is yet to come. Doesn't anyone else want to make some money?

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: W Shakespeare who wrote (8)12/28/2000 12:27:29 AM
From: W Shakespeare
   of 96
 
Happy holidays to everyone on the CPTS board! I look forward to another triple in CPTS stock in 2001.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: W Shakespeare who wrote (9)1/3/2001 2:35:31 PM
From: W Shakespeare
   of 96
 
Conceptus Announces Early Attainment of Patient Enrollment Goal for Stop Pivotal Trial; Accelerates PMA Filing; Sets Milestones for International Product Launches


SAN CARLOS, Calif.--(BW HealthWire)--Jan. 3, 2001--Conceptus, Inc. (Nasdaq NM:CPTS) announced that bilateral placement has been achieved in more than 400 patients in the pivotal clinical study of the STOP(TM) (Selective Tubal Occlusion Procedure) non-surgical permanent contraception device for women.

The pivotal study is designed to obtain 12-month effectiveness data on 400 patients with bilateral placement to support a Pre-Market Approval (PMA) application. Accordingly, the PMA application filing timeline is expected to be accelerated by approximately three months.

Enrollment in the multi-center, international pivotal clinical trial for STOP commenced in May of 2000. Additional patients will be enrolled over the next several weeks to replace any patients who may be lost-to-follow-up or who cannot be evaluated for other reasons. The pivotal trial will examine safety, effectiveness, and patient comfort during the placement procedure and subsequent use of the STOP device.

"The rapid enrollment we've experienced in the STOP trial highlights the desire women have for a new permanent contraceptive option, and demonstrates the tremendous commitment of the physicians and their staffs at all of the investigational sites," said Jay M. Cooper, M.D., founder and medical director of Women's Health Research Center, Phoenix, Arizona, and the principal U.S. investigator of STOP.

"The enthusiasm of our STOP clinical investigation team coupled with targeted advertising helped us to achieve this important milestone ahead of plan," said Steven Bacich, president and chief executive officer of Conceptus. "Accordingly, our expenses in the fourth quarter of 2000 will reflect this higher level of patient enrollment."

The pivotal study protocol requires 12 months of follow-up after each patient begins to rely exclusively on STOP for contraception, which occurs three months after the STOP placement procedure. As such, Conceptus is working towards a PMA filing with the FDA during the third quarter of 2002.

"Australia will be the first country where STOP is commercially available. We have already received both Therapeutic Goods Administration listing and a reimbursement code comparable to that of surgical tubal ligation, and we are making excellent progress towards a product launch during the first quarter of 2001," according to Mr. Bacich. "In Australia, we will be marketing STOP ourselves, and we continue to speak with prospective co-marketing partners, as well."

Commenting on the outlook in Europe, Conceptus expects to receive the CE Mark from a Notified Body in the very near future. Upon receipt of the CE Mark, plans call for conducting reimbursement studies and securing one or more partners for sales and marketing, as well as initiating the Decentralized Mutual Recognition procedure of the European Union, which covers 11 European countries. The first commercial sales of STOP in select European markets are expected in 2001.

Permanent Contraception

Surgical tubal ligation has become the most common form of contraception worldwide, despite the fact that it is invasive and costly. In the U.S., about 93% of such procedures are performed in a hospital or surgi-center under general anesthesia, requiring 4-5 hours of hospital recovery time and resulting in 3-4 days off work. A STOP procedure does not require cutting or penetration of the abdomen, is typically performed with local anesthetic and can be performed in a less costly office setting. Accordingly, a woman is expected to spend about 2-3 hours of her day for a STOP procedure, with a rapid return to normal activities.

About Conceptus

Conceptus, Inc. is developing STOP, an innovative medical device and procedure designed to provide a non-surgical alternative to tubal ligation, the leading form of contraception worldwide. The STOP device is a unique and proprietary micro-coil designed to be deployed permanently into each fallopian tube using the Company's minimally invasive transcervical tubal access catheter system. Once in place, clinical studies have shown that the STOP device induces an occlusive tissue response.

Data from the United Nations show that worldwide, 30% of reproductive couples using contraception rely on surgical tubal ligation. Additionally, a survey performed by the Centers for Disease Control and Prevention indicates that surgical tubal ligation continues to be the most prevalent form of contraception in the U.S., and that 35% of women age 35-44 have had a surgical tubal sterilization. An estimated 800,000 surgical tubal ligations are performed each year in the U.S. Additional information about the Company and the STOP device is available at www.conceptus.com.

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. The receipt of regulatory approvals, results of product development programs, and clinical efficacy of and market demand for products, among other matters discussed in this release, may differ significantly from the discussion of such matters in the forward-looking statements. Such differences may be based upon factors within the Company's control, such as strategic planning decisions by management and re-allocation of internal resources, or on factors outside of the Company's control, such as delays by regulatory authorities, scientific advances by third parties and introduction of competitive products, as well as those factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 1999 and other filings with the Securities and Exchange Commission.

CONTACT:

Conceptus, Inc.

Oliver Brouse, Director, Finance, 650/802-7297

oliverb@conceptus.com

Stan Van Gent, VP, Marketing, 650/413-1603

stanv@conceptus.com

www.conceptus.com

or

Lippert Heilshorn & Associates

Investor Contacts

Bruce Voss, 310/575-4848 (Bruce@lhai.com)

Kim Golodetz, 212/838-3777 (Kim@lhai.com)

Financial Media Contact

Elissa Grabowski, 212/838-3777 (Elissa@lhai.com)

www.lhai.com

or

Cohn & Wolfe

General Media Contact

Lynn Kenney, 212/798-9766

Lynn-Kenney@nyc.cohnwolfe.com

KEYWORD: CALIFORNIA







BW2002 JAN 03,2001

1:00 PACIFIC

4:00 EASTERN

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: W Shakespeare who wrote (10)1/20/2001 1:35:24 PM
From: W Shakespeare
   of 96
 
Conceptus Conference Call With Adams, Harkness & Hill Available On the Web


SAN CARLOS, Calif.--(BW HealthWire)--Jan. 16, 2001--Conceptus, Inc. (NASDAQ NM:CPTS), the developer of the STOP(TM) non-surgical permanent contraception device for women, today announced that it will be participating in a conference call sponsored by the investment bank Adams, Harkness & Hill on January 16, 2001 beginning at 2:00 p.m. eastern time.

Steven Bacich, president and chief executive officer, and Jay Cooper, M.D. and U.S. lead clinical investigator, will provide an overview of the company's progress to the bank's institutional clients.

Individuals interested in listening to the conference call via the Internet may do so through Vcall at www.vcall.com. To listen to the live call, please visit the Web site at least 15 minutes prior to the start of the call to register, download and install the necessary audio software. A replay will be available on the site for 90 days. The conference call may also be accessed on the company's web site, www.conceptus.com.

Conceptus, Inc. is developing STOP(TM), an innovative medical device designed to provide a non-surgical alternative to the leading form of contraception worldwide, surgical tubal sterilization. Data from the United Nations show that worldwide, 30% of reproductive couples using contraception rely on surgical tubal sterilization. A survey performed by the Centers for Disease Control indicates that surgical tubal sterilization is the No. 1 form of contraception in the U.S., and that 35% of women age 35-44 have had a surgical tubal sterilization. An estimated 800,000 tubal ligations are performed each year in the U.S., of which 90% are performed in a hospital or surgi-center and require general anesthesia.

STOP is a proprietary micro-coil that is designed to be deployed permanently into each fallopian tube using the Company's minimally invasive tubal access and delivery system and a unique delivery wire. Once in place, STOP is designed to induce a benign tissue response that occludes the lumen of the fallopian tubes.

CONTACT:

Conceptus, Inc.

Company Contacts:

Oliver Brouse, Director, Finance, 650/802-7240

oliverb@conceptus.com

Stan Van Gent, VP, Marketing, 650/413-1603

stanv@conceptus.com

www.conceptus.com

or

Lippert Heilshorn & Associates

Investor Contacts:

Bruce Voss, 310/575-4848 (Bruce@lhai.com)

Kim Golodetz, 212/838-3777 (Kim@lhai.com)

Financial Media Contact:

Elissa Grabowski, 212/838-3777 (Elissa@lhai.com)

www.lhai.com

or

Cohn & Wolfe

General Media Contact:

Lynn Kenney, 212/798-9766

Lynn-Kenney@nyc.cohnwolfe.com

KEYWORD: CALIFORNIA







BW2015 JAN 16,2001

1:00 PACIFIC

4:00 EASTERN

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: W Shakespeare who wrote (11)1/24/2001 8:35:49 AM
From: telephonics
   of 96
 
Bill,I cannot find the conference on the vcall site. Can you provide a URL or other clue,please

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: telephonics who wrote (12)1/24/2001 11:16:10 AM
From: W Shakespeare
   of 96
 
telephonics,
Once you get to the vcall site, enter CPTS towards the top of the page in a box labeled SEARCH, then hit GO and it will take you to the conference call. Have you read today's press release yet?

Conceptus Receives Patent Protection For Stop Non-Surgical Permanent Contraception Procedure


SAN CARLOS, Calif.--(BW HealthWire)--Jan. 24, 2001--Conceptus, Inc. (Nasdaq NM: CPTS), developer of the STOP(TM) (Selective Tubal Occlusion Procedure) non-surgical permanent contraception procedure for women, today announced the issuance of a U.S. patent covering its STOP technology. The patent, number 6176240, entitled "Contraceptive Transcervical Fallopian Tube Occlusion Devices and their Delivery" allows a number of claims covering technology in which intrafallopian devices are anchored by resilient coils. The patent also describes a variety of techniques to enhance retention of these devices, including attaching polyester fibers to the device and allows method claims covering the transcervical placement of the STOP system.

"The issuance of this patent is an additional indication regarding the strength of our technology and market position in the United States," commented Ashish Khera, Vice President of Research and Development for Conceptus. "We are particularly pleased with the breadth of the protection provided in this patent which covers several functional aspects of our system."

Permanent Contraception

Surgical tubal ligation has become the most common form of contraception worldwide, despite the fact that it is invasive and costly. In the U.S., about 93% of such procedures are performed in a hospital or surgi-center under general anesthesia, requiring 4-5 hours of hospital recovery time and resulting in 3-4 days off work. A STOP procedure does not require cutting or penetration of the abdomen, is typically performed with local anesthetic and can be performed in a less costly office setting. Accordingly, a woman is expected to spend about 2-3 hours of her day for a STOP procedure, with a rapid return to normal activities.

About Conceptus

Conceptus, Inc. is developing STOP, an innovative medical device and procedure designed to provide a non-surgical alternative to tubal ligation, the leading form of contraception worldwide. The STOP device is a unique and proprietary micro-coil designed to be deployed permanently into each fallopian tube using the Company's minimally invasive transcervical tubal access catheter system. Once in place, clinical studies have shown that the STOP device induces an occlusive tissue response.

Data from the United Nations show that worldwide, 30% of reproductive couples using contraception rely on surgical tubal ligation. Additionally, a survey performed by the Centers for Disease Control and Prevention indicates that surgical tubal ligation continues to be the most prevalent form of contraception in the U.S., and that 35% of women age 35-44 have had a surgical tubal sterilization. An estimated 800,000 surgical tubal ligations are performed each year in the U.S. Additional information about the Company and the STOP device is available at www.conceptus.com.

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. The receipt of regulatory approvals, results of product development programs, and clinical efficacy of and market demand for products, among other matters discussed in this release, may differ significantly from the discussion of such matters in the forward-looking statements. Such differences may be based upon factors within the Company's control, such as strategic planning decisions by management and re-allocation of internal resources, or on factors outside of the Company's control, such as delays by regulatory authorities, scientific advances by third parties and introduction of competitive products, as well as those factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 1999 and other filings with the Securities and Exchange Commission.

CONTACT:

Conceptus, Inc.

Oliver Brouse, 650/802-7297

oliverb@conceptus.com

Stan Van Gent, 650/413-1603

stanv@conceptus.com

www.conceptus.com

or

Investor Contacts:

Lippert Heilshorn & Associates

Bruce Voss (Bruce@lhai.com)

310/691-7104

Kim Golodetz (Kim@lhai.com)

212/838-3777

Financial Media Contact:

Elissa Grabowski (Elissa@lhai.com)

212/838-3777

www.lhai.com

or

General Media Contact:

Cohn & Wolfe

Lynn Kenney, 212/798-9766

Lynn-Kenney@nyc.cohnwolfe.com

KEYWORD: CALIFORNIA







BW2006 JAN 24,2001

1:00 PACIFIC

4:00 EASTERN

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10 

Copyright © 1995-2017 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.